X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA AUROBINDO PHARMA NATCO PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 18.8 14.1 132.8% View Chart
P/BV x 18.0 3.7 492.4% View Chart
Dividend Yield % 0.6 0.4 148.9%  

Financials

 NATCO PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
AUROBINDO PHARMA
Mar-17
NATCO PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs877895 98.0%   
Low Rs424622 68.1%   
Sales per share (Unadj.) Rs223.4254.6 87.8%  
Earnings per share (Unadj.) Rs31.139.3 79.1%  
Cash flow per share (Unadj.) Rs40.346.6 86.5%  
Dividends per share (Unadj.) Rs5.002.50 200.0%  
Dividend yield (eoy) %0.80.3 233.3%  
Book value per share (Unadj.) Rs219.5160.0 137.2%  
Shares outstanding (eoy) m33.07585.88 5.6%   
Bonus/Rights/Conversions PAESOP-  
Price / Sales ratio x2.93.0 97.7%   
Avg P/E ratio x20.919.3 108.4%  
P/CF ratio (eoy) x16.116.3 99.1%  
Price / Book Value ratio x3.04.7 62.5%  
Dividend payout %16.16.4 252.9%   
Avg Mkt Cap Rs m21,504444,390 4.8%   
No. of employees `000NA14.0 0.0%   
Total wages/salary Rs m1,12817,678 6.4%   
Avg. sales/employee Rs ThNM10,667.8-  
Avg. wages/employee Rs ThNM1,264.3-  
Avg. net profit/employee Rs ThNM1,645.8-  
INCOME DATA
Net Sales Rs m7,389149,157 5.0%  
Other income Rs m1671,159 14.4%   
Total revenues Rs m7,556150,316 5.0%   
Gross profit Rs m1,79334,343 5.2%  
Depreciation Rs m3044,276 7.1%   
Interest Rs m366667 54.9%   
Profit before tax Rs m1,29030,558 4.2%   
Minority Interest Rs m4650 92.2%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3097,597 4.1%   
Profit after tax Rs m1,02723,012 4.5%  
Gross profit margin %24.323.0 105.4%  
Effective tax rate %23.924.9 96.3%   
Net profit margin %13.915.4 90.1%  
BALANCE SHEET DATA
Current assets Rs m3,68192,062 4.0%   
Current liabilities Rs m3,12366,223 4.7%   
Net working cap to sales %7.617.3 43.6%  
Current ratio x1.21.4 84.8%  
Inventory Days Days89106 84.4%  
Debtors Days Days5968 86.7%  
Net fixed assets Rs m7,68562,919 12.2%   
Share capital Rs m331586 56.4%   
"Free" reserves Rs m6,67093,133 7.2%   
Net worth Rs m7,25993,719 7.7%   
Long term debt Rs m9551,814 52.6%   
Total assets Rs m11,957162,494 7.4%  
Interest coverage x4.546.8 9.7%   
Debt to equity ratio x0.10 679.6%  
Sales to assets ratio x0.60.9 67.3%   
Return on assets %11.714.6 80.0%  
Return on equity %14.224.6 57.6%  
Return on capital %20.732.7 63.3%  
Exports to sales %39.40-   
Imports to sales %5.70-   
Exports (fob) Rs m2,908NA-   
Imports (cif) Rs m421NA-   
Fx inflow Rs m3,44575,838 4.5%   
Fx outflow Rs m70330,224 2.3%   
Net fx Rs m2,74345,613 6.0%   
CASH FLOW
From Operations Rs m1,44032,786 4.4%  
From Investments Rs m-1,089-17,870 6.1%  
From Financial Activity Rs m-353-19,153 1.8%  
Net Cashflow Rs m-1-4,239 0.0%  

Share Holding

Indian Promoters % 52.0 54.1 96.2%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 8.0 98.6%  
FIIs % 16.6 27.7 60.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 10.2 254.9%  
Shareholders   25,395 69,601 36.5%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   DIVIS LABORATORIES  WOCKHARDT LTD.  VENUS REMEDIES  FRESENIUS KABI ONCO.  FDC LTD.  

Compare NATCO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Surges 200 Points; Energy Stocks Top Gainers(Closing)

After opening the day in green, share markets in India witnessed positive trading activity throughout the day and ended the day in green.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 0.4%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 0.4% YoY). Sales on the other hand came in at Rs 40 bn (up 11.2% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 69.6%

May 25, 2018 | Updated on May 25, 2018

For the quarter ended March 2018, NATCO PHARMA has posted a net profit of Rs 3 bn (up 69.6% YoY). Sales on the other hand came in at Rs 8 bn (up 32.9% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Real Truth About India's FDI, Beyond WhatsApp(Vivek Kaul's Diary)

Jul 4, 2018

The FDI numbers do not look very impressive once we adjust for repatriations as well as the overall growth in the economy.

How to Avoid a 90% Loss Suffered by This Super Investor(The 5 Minute Wrapup)

Jul 12, 2018

Blindly following super investors is a dangerous game to play. Here's how you can avoid such mistakes.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

New Fund Offer - ICICI Prudential Pharma Healthcare and Diagnostics Fund - Should You Invest?(Outside View)

Jul 6, 2018

ICICI AMC launches an open -ended equity fund following Pharma, Healthcare, Diagnostic and allied theme.

When Disappointment Panda is Around. Buy Quality Stock like This!(Chart Of The Day)

Jul 6, 2018

Buy Companies that can fight all kinds of Pandas and Bears in the long run.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Jul 17, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - SUVEN LIFE COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS